Daily Stock Analysis, BLUE, bluebird bio Inc, priceseries

bluebird bio Inc. Daily Stock Analysis
Stock Information
Open
6.79
Close
7.24
High
7.39
Low
6.75
Previous Close
6.93
Daily Price Gain
0.31
YTD High
10.74
YTD High Date
Jan 4, 2022
YTD Low
6.75
YTD Low Date
Jan 21, 2022
YTD Price Change
-3.36
YTD Gain
-31.70%
52 Week High
31.68
52 Week High Date
Feb 8, 2021
52 Week Low
6.75
52 Week Low Date
Jan 21, 2022
52 Week Price Change
-22.97
52 Week Gain
-76.03%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 23. 2017
50.71
Mar 6. 2017
54.54
7 Trading Days
7.55%
Link
LONG
Jun 2. 2017
54.50
Jun 23. 2017
70.97
15 Trading Days
30.22%
Link
LONG
Aug 22. 2017
61.82
Sep 21. 2017
83.29
21 Trading Days
34.73%
Link
LONG
Dec 7. 2017
108.74
Dec 22. 2017
114.33
11 Trading Days
5.13%
Link
LONG
Jan 17. 2018
113.50
Feb 2. 2018
129.21
12 Trading Days
13.83%
Link
LONG
Mar 2. 2018
133.48
Mar 14. 2018
140.38
8 Trading Days
5.17%
Link
LONG
Jun 27. 2019
80.25
Jul 29. 2019
88.49
21 Trading Days
10.28%
Link
LONG
Oct 7. 2021
12.23
Oct 21. 2021
13.28
10 Trading Days
8.58%
Link
LONG
Oct 22. 2021
13.47
Nov 5. 2021
14.73
10 Trading Days
9.37%
Link
Company Information
Stock Symbol
BLUE
Exchange
NasdaqGS
Company URL
http://www.bluebirdbio.com
Company Phone
339-499-9300
CEO
Nick Leschly
Headquarters
Massachusetts
Business Address
60 BINNEY STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001293971
About

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.